Physician profile
Ana Kumar
NPI 1215905971
$1,000.63
in general payments reported to CMS, 2019-2025
9 companies · $223 in 2025
The $223 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $22.76 · 2021: $98.44 · 2022: $155 · 2023: $170 · 2024: $209 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $456 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $456.32 |
| Education | $144.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $376.46 | 2019-2025 | Tavneos, Uplizna, Evenity |
| Abbvie INC. | $236.67 | 2021-2025 | |
| Inogen, INC. | $160.41 | 2022-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Lilly USA, LLC | $89.76 | 2019 | |
| Novartis Pharmaceuticals Corporation | $34.53 | 2025 | |
| Glaxosmithkline, LLC. | $30.61 | 2024-2025 | Benlysta |
| Astrazeneca Pharmaceuticals Lp | $28.03 | 2024-2025 | Saphnelo |
| Lundbeck LLC | $22.76 | 2020 | |
| Bioventus LLC | $21.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ana Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.